Harvest Portfolios Group Inc. Acquires 15,499 Shares of Stryker Corporation $SYK

Harvest Portfolios Group Inc. increased its holdings in Stryker Corporation (NYSE:SYK) by 10.4% in the 4th quarter, Holdings Channel reports. The fund owned 164,367 shares of the medical technology company’s stock after buying an additional 15,499 shares during the quarter. Harvest Portfolios Group Inc.’s holdings in Stryker were worth $57,770,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Stryker by 4.4% in the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after acquiring an additional 96,662 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Stryker by 4.5% in the 3rd quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after acquiring an additional 80,536 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of NYSE SYK opened at $317.81 on Wednesday. The firm’s 50-day moving average price is $327.61 and its 200-day moving average price is $350.70. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $121.84 billion, a PE ratio of 36.78, a PEG ratio of 1.97 and a beta of 0.80. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research reports. Leerink Partners initiated coverage on shares of Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target for the company. BTIG Research decreased their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Truist Financial restated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Insider Activity

In other news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.